Knight Therapeutics (OTCMKTS:KHTRF) Trading Down 0.6% – Here’s Why

by · The Markets Daily

Knight Therapeutics Inc. (OTCMKTS:KHTRF – Get Free Report)’s share price was down 0.6% during mid-day trading on Monday . The stock traded as low as $4.2920 and last traded at $4.2920. Approximately 500 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 3,114 shares. The stock had previously closed at $4.3180.

Knight Therapeutics Stock Down 0.6%

The business’s fifty day moving average is $4.25 and its 200-day moving average is $4.41.

Knight Therapeutics Company Profile

(Get Free Report)

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

See Also